LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 21 of 166
Next
>>
>
501 to 525 of 4140 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Timepoint	Timepoint Unit	Mean Total Cell Count Before Treatment	Mean Total Cell Count After Treatment	Mean Total Control Cell Count	Mean Relative Cell Count	Mean Normalized Growth Rate Inhibition Value
BT-20	GSK1904529A	0.12	uM	LJP6	72	hr	1657	4877	5383	0.9056	0.8860
BT-20	GSK1904529A	0.37	uM	LJP6	72	hr	1657	5067	5383	0.9418	0.9307
BT-20	Linsitinib	0.04	uM	LJP5	72	hr	1657	4776	5588	0.8550	0.8287
BT-20	Linsitinib	0.12	uM	LJP5	72	hr	1657	4955	5588	0.8869	0.8675
BT-20	Linsitinib	1.11	uM	LJP5	72	hr	1657	4955	5588	0.8867	0.8673
BT-20	Linsitinib	3.33	uM	LJP5	72	hr	1657	4834	5588	0.8654	0.8410
BT-20	Ruxolitinib	0.12	uM	LJP5	72	hr	1657	5224	5588	0.9350	0.9247
BT-20	Ruxolitinib	0.37	uM	LJP5	72	hr	1657	5138	5588	0.9196	0.9066
BT-20	Ruxolitinib	3.33	uM	LJP5	72	hr	1657	4811	5588	0.8612	0.8366
BT-20	Ruxolitinib	10	uM	LJP5	72	hr	1657	3984	5588	0.7130	0.6490
BT-20	Seliciclib	0.04	uM	LJP5	72	hr	1657	5718	5588	1.0234	1.0266
BT-20	Seliciclib	0.12	uM	LJP5	72	hr	1657	5585	5588	0.9996	0.9994
BT-20	Seliciclib	1.11	uM	LJP5	72	hr	1657	4763	5588	0.8525	0.8258
BT-20	Seliciclib	3.33	uM	LJP5	72	hr	1657	4547	5588	0.8139	0.7783
BT-20	AT-7519	0.12	uM	LJP6	72	hr	1657	4313	5383	0.8018	0.7564
BT-20	AT-7519	0.37	uM	LJP6	72	hr	1657	1889	5383	0.3511	0.0799
BT-20	AT-7519	3.33	uM	LJP6	72	hr	1657	1217	5383	0.2261	-0.1671
BT-20	AT-7519	10	uM	LJP6	72	hr	1657	922	5383	0.1714	-0.2941
BT-20	AZD7762	1.11	uM	LJP6	72	hr	1657	2517	5383	0.4683	0.2793
BT-20	AZD7762	3.33	uM	LJP6	72	hr	1657	1552	5383	0.2891	-0.0378
BT-20	AZD8055	0.04	uM	LJP6	72	hr	1657	2584	5383	0.4793	0.2957
BT-20	AZD8055	0.12	uM	LJP6	72	hr	1657	2341	5383	0.4347	0.2245
BT-20	AZD8055	3.33	uM	LJP6	72	hr	1657	1826	5383	0.3392	0.0581
BT-20	Fedratinib	0.37	uM	LJP5	72	hr	1657	5280	5588	0.9449	0.9362
BT-20	Fedratinib	0.12	uM	LJP5	72	hr	1657	5395	5588	0.9655	0.9603

|<
<<
Previous
Page 21 of 166
Next
>>
>
501 to 525 of 4140 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)